angiotensin-converting enzyme inhibitor + angiotensin receptor blocker

This refers to the combination therapy of an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB), two classes of antihypertensive drugs that both target the renin-angiotensin system but at different points. ACE inhibitors block the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, while ARBs prevent angiotensin II from binding to its receptors. Both are used individually for hypertension, heart failure, and chronic kidney disease with proteinuria. The rationale for combining these agents is based on their complementary mechanisms—potentially providing more complete inhibition of the renin-angiotensin system than either alone. However, clinical studies have shown only modest additive effects on blood pressure reduction and some benefit in reducing proteinuria in chronic kidney disease; there is also increased risk of adverse effects such as hyperkalemia and acute kidney injury when used together[2][5][6]. Most guidelines recommend against routine combined use due to safety concerns[9].

Other names

ACE inhibitor + ARBACEI + ARBangiotensin-converting enzyme inhibitor and angiotensin receptor blocker